242 related articles for article (PubMed ID: 26287854)
1. PCSK9 Inhibitors and Cardiovascular Events.
Robinson JG; Kastelein JJ
N Engl J Med; 2015 Aug; 373(8):774. PubMed ID: 26287854
[No Abstract] [Full Text] [Related]
2. PCSK9 Inhibitors and Cardiovascular Events.
Auer J; Berent R; Primus C
N Engl J Med; 2015 Aug; 373(8):773. PubMed ID: 26287855
[No Abstract] [Full Text] [Related]
3. PCSK9 Inhibitors and Cardiovascular Events.
Sabatine MS; Wasserman SM; Stein EA
N Engl J Med; 2015 Aug; 373(8):774-5. PubMed ID: 26295078
[No Abstract] [Full Text] [Related]
4. PCSK9 Inhibitors and Cardiovascular Events.
Goemann IM; Londero TM; Dora JM
N Engl J Med; 2015 Aug; 373(8):773-4. PubMed ID: 26287856
[No Abstract] [Full Text] [Related]
5. PCSK9 inhibitors reduce cardiovascular events, preliminary data show.
Mayor S
BMJ; 2015 Mar; 350():h1508. PubMed ID: 25782694
[No Abstract] [Full Text] [Related]
6. Lowering LDL cholesterol is good, but how and in whom?
Stone NJ; Lloyd-Jones DM
N Engl J Med; 2015 Apr; 372(16):1564-5. PubMed ID: 25773740
[No Abstract] [Full Text] [Related]
7. Dyslipidaemia. Assessing the efficacy and safety of evolocumab and alirocumab.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):261. PubMed ID: 25824512
[No Abstract] [Full Text] [Related]
8. PCSK9 inhibition: the next statin?
Vogel RA
J Am Coll Cardiol; 2012 Jun; 59(25):2354-5. PubMed ID: 22465426
[No Abstract] [Full Text] [Related]
9. Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial.
Kazi DS; Penko J; Coxson PG; Moran AE; Ollendorf DA; Tice JA; Bibbins-Domingo K
JAMA; 2017 Aug; 318(8):748-750. PubMed ID: 28829863
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events.
Robinson JG; Farnier M; Krempf M; Bergeron J; Luc G; Averna M; Stroes ES; Langslet G; Raal FJ; El Shahawy M; Koren MJ; Lepor NE; Lorenzato C; Pordy R; Chaudhari U; Kastelein JJ;
N Engl J Med; 2015 Apr; 372(16):1489-99. PubMed ID: 25773378
[TBL] [Abstract][Full Text] [Related]
11. Updates on prevention: obesity, ezetimibe, PCSK9, and HIV infection.
Lüscher TF
Eur Heart J; 2016 Dec; 37(48):3545-3548. PubMed ID: 28087743
[No Abstract] [Full Text] [Related]
12. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
Sahebkar A; Watts GF
Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
[TBL] [Abstract][Full Text] [Related]
13. Do PCSK9 inhibitors reduce cardiovascular events?
Kolber MR; Nickonchuk T; Turgeon R
Can Fam Physician; 2018 Sep; 64(9):669. PubMed ID: 30209099
[No Abstract] [Full Text] [Related]
14. [Lipid control in high-risk patients: focus on PCSK9 inhibitors].
Filardi PP; Paolillo S; Trimarco B
G Ital Cardiol (Rome); 2015 Jan; 16(1):44-51. PubMed ID: 25689751
[TBL] [Abstract][Full Text] [Related]
15. Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs.
Everett BM; Smith RJ; Hiatt WR
N Engl J Med; 2015 Oct; 373(17):1588-91. PubMed ID: 26444323
[No Abstract] [Full Text] [Related]
16. Is intensive LDL-cholesterol lowering beneficial and safe?
Cheung BM; Lam KS
Lancet; 2010 Nov; 376(9753):1622-4. PubMed ID: 21067806
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.
Sabatine MS; Giugliano RP; Wiviott SD; Raal FJ; Blom DJ; Robinson J; Ballantyne CM; Somaratne R; Legg J; Wasserman SM; Scott R; Koren MJ; Stein EA;
N Engl J Med; 2015 Apr; 372(16):1500-9. PubMed ID: 25773607
[TBL] [Abstract][Full Text] [Related]
18. New Drugs for Lowering LDL-Cholesterol.
Bădescu C; Rezuş E; Bădescu L; Dima N; Rezuş C
Rev Med Chir Soc Med Nat Iasi; 2016; 120(3):485-90. PubMed ID: 30044561
[TBL] [Abstract][Full Text] [Related]
19. Lipid parameters and cardiovascular events in patients taking statins.
Brook RD; Rubenfire M
JAMA; 2012 Jul; 308(2):132; author reply 132-3. PubMed ID: 22782403
[No Abstract] [Full Text] [Related]
20. Lipid parameters and cardiovascular events in patients taking statins.
Martin SS; Jones SR
JAMA; 2012 Jul; 308(2):131-2; author reply 132-3. PubMed ID: 22782402
[No Abstract] [Full Text] [Related]
[Next] [New Search]
